全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 133454-47-4 |
|---|---|---|---|
| 分子式 | C24H27FN2O4 | 纯度 | ＞98% |
| 分子量 | 426.48 | 货号 | abs47027746 |
| 规格 | 5mg | 供货周期 | 现货 |
| 主要用途 | is an atypical antipsychotic | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Iloperidone 133454-47-4
| 产品描述 | |
| 描述 | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. made initial inquiries into the drug; however, in May 1996, they discontinued research, and in June 1997 gave research rights to Titan Pharmaceuticals. Titan then handed over worldwide development, manufacturing and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals announced that the Phase III development rights have been acquired by Vanda Pharmaceuticals. FDA approved on May 9, 2009. |
| 纯度 | ＞98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | 伊潘立酮；HP 873 |
| 外观 | 白色至灰白色结晶粉末 |
| 可溶性/溶解性 | DMSO : 26 mg/mL (61 mM) Ethanol : 4 mg/mL (9.37 mM) |
| 生物活性 | |
| 靶点 | 5-HT |
| In vitro(体外研究) | Iloperidone displays high affinity (Ki Iloperidone displays higher affinity for the dopamine D3 receptor (Ki = 7.1 nM) than for the dopamine D4 receptor (Ki = 25 nM). Iloperidone displays high affinity for the 5-HT6 and 5-HT7 receptors (Ki = 42.7 nM and 21.6 nM, respectively), and is found to have higher affinity for the 5-HT2A (Ki = 5.6 nM) than for the 5-HT2C receptor (Ki = 42.8 nM). Iloperidone significantly increases dopa accumulation, an index of dopamine turnover in response to D2 receptor blockade, at doses from 0.3 mg/kg to 10 mg/kg i.p. in the striatum and from 1 mg/kg to 10 mg/kg in the nucleus accumbens. |
| In vivo(体内研究) | Iloperidone exerts behavioral effects in pharmacological rats models of disrupted sensorimotor gating consistent with "atypical" antipsychotics, mediated by antagonism of dopaminergic and noradrenergic receptors. Iloperidone (1 and 3 mg/kg) prevents the PPI-disruptive effects of treatment with 1 mg/kg PCP. Iloperidone (0.3 mg/kg) prevents cirazoline-induced PPI deficits, independent of its effects on startle magnitude. Iloperidone (10 mg/kg) and Melperone (10 mg/kg) produce an equivalent or a smaller increase in DA release in the nucleus accumbens (NAC) of rats, respectively, compared to the mPFC, whereas none of them increase acetylcholine (ACh) release in the NAC. |
| 参考文献 | |
| 参考文献 |
|
| 研究领域 | |
| 研究领域 | MetabolismTypes of diseaseObesity NeuroscienceProcesses NeuroscienceNeurology processMetabolism NeuroscienceNeurotransmissionReceptors / ChannelsGPCRSerotonin Receptors Signal TransductionSignaling PathwayG Protein SignalingGPCR Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：